Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Trailing rivals, AbbVie scores win with dual-acting myeloma drug

4 September 2026 · By · Wire by Fusion42

Published

4 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at biopharmadive.com →

◆ Verified

Fusion42 · 4 September 2026 · Fusion42 review

AbbVie is advancing its dual-acting myeloma drug etentamig towards FDA submission, highlighting a better side effect profile compared to competitors from J&J, Pfizer, and Regeneron.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You face a narrowing market window as AbbVie pushes a treatment with fewer side effects that may reshape competition. This raises the bar for new myeloma treatments and pressures you to innovate beyond safety profiles.

◆ Coverage

1 source · 4 Sep 2026

◆ Related on Wire

◆ Topics

Biotechmyelomadrug-approvalbiotechfdaabbvie